Uncategorized

Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs

Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its inhaled versions of approved respiratory drugs.​Read More

Published

12 hours ago

on

Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its inhaled versions of approved respiratory drugs.​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version